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A B S T R A C T
The World Health Organization (WHO) serves as a key organization to bring together experts along the
continuum of vaccine development and regulatory approval, among its other functions. Using the revision of
WHO's guidelines on prophylactic human papillomavirus (HPV) vaccine as an example, we describe the process
by which (1) a need to revise the guidelines was identiﬁed; (2) a group of stakeholders with complementary
expertise and key questions were identiﬁed; (3) a scientiﬁc review was conducted; (4) consensus on revisions
was achieved; (5) guidelines were updated, reviewed widely, and approved. This multi-year process resulted in
the consensus that regulatory agencies could consider additional endpoints, such as persistent HPV infection or
immune equivalence, depending on the design of the HPV vaccine trials. Updating the guidelines will now
accelerate vaccine development, reduce costs of clinical trials, and lead to faster regulatory approval.
1. Introduction
The process to recommend a commercial vaccine has multiple steps
and safeguards taken to generate international consensus among
multiple stakeholders. This process ensures that recommendations
are based on the quality of scientiﬁc data and are made with the health
of the public in mind. Using the World Health Organization's (WHO)
recent revision of its recommendations and standards for prophylactic
human papillomavirus (HPV) vaccines, “Guidelines to assure the
quality, safety and eﬃcacy of recombinant human papillomavirus
virus-like particle vaccines” (Technical Report Series 962, Annex 1),
as an example, we describe the multi-year, multi-step process that was
undertaken to arrive at the updated guidance [1].
WHO's global written standards, the Technical Report Series (TRS),
serve many functions: (1) to provide guidance for national regulatory
agencies and manufacturers to assure vaccine quality, safety, and
eﬃcacy; (2) to serve as the basis for national legislation; and (3) to
represent WHO vaccine prequaliﬁcation, thereby legitimizing vaccine
procurement by United Nations agencies.
In 2006, the WHO established the technical guidelines to assure the
quality, safety, and eﬃcacy for prophylactic HPV L1-virus-like particle
(VLP) vaccines (TRS 962, Annex 1) [1]. These recommendations were
developed in the context of the safety and eﬃcacy of the recently
available prophylactic vaccines at that time, the bivalent (Cervarix,
GlaxoSmithKline) and quadrivalent (Gardasil, Merck) recombinant
VLP HPV vaccines [1]. Both of these ﬁrst-generation HPV vaccines
target HPV types 16 and 18, which are associated with 70% of the
global cervical cancer burden, and the quadrivalent vaccine also targets
non-oncogenic HPV types 6 and 11 [2]. Primary data demonstrated
very strong eﬃcacy for both vaccines against the disease endpoints for
licensure: high-grade pre-invasive lesions of the cervix, vulva, and
vagina [3,4].
In 2009, the WHO published a position paper on prophylactic HPV
vaccines, recommending the routine use of these vaccines in national
immunization programs [5], and both vaccines were pre-qualiﬁed by
the WHO that same year. These two steps enabled international global
health partnerships to procure and distribute the HPV vaccine. In
subsequent years, advances in HPV vaccine research compelled the
WHO to consider revising its guidance on vaccine eﬃcacy evaluation –
speciﬁcally, whether or not to consider alternate clinical endpoints for
next-generation vaccine trials.
In this paper, we summarize the process implemented by the WHO
to (1) identify a need for guideline revision; (2) assemble stakeholders
to establish relevant questions; (3) critically review the current
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evidence on HPV epidemiology; (4) establish consensus on appropriate
clinical endpoints for regulatory evaluation of next-generation HPV
vaccines; and (5) update guidelines. Fig. 1 presents a timeline of this
process. These key steps were necessary for the approval of the new
guidance, named “Recommendations to assure the quality, safety, and
eﬃcacy of recombinant human papillomavirus virus-like particle
vaccines” in October 2015 [6].
2. Identifying a need for guideline revision
Pivotal trials for the current L1-VLP vaccines against HPV types 16
and 18 were powered for eﬃcacy against a disease endpoint, CIN2+.
This outcome was chosen due to the unethical and impractical nature
of waiting for development of cervical cancer. Given high vaccine
eﬃcacy among vaccine-type naïve patients, these vaccines reduce the
incidence of preinvasive lesions signiﬁcantly [4].
With proven eﬃcacy of current vaccines, increasing understanding
of HPV epidemiology, and ongoing innovation of next-generation HPV
vaccines, the WHO initiated a process to evaluate additional trial
endpoints for new prophylactic HPV vaccine trials in 2012. The WHO
recognized the need for next-generation HPV vaccines. New vaccines
could allow for several innovations: increased coverage of non-16/18
oncogenic disease, new production and delivery platforms, potential
use in younger age ranges, simpler administration schedules and
Fig. 1. A timeline of HPV vaccine adoption and corresponding WHO guidelines, with a focus on guideline revision.
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routes, and prevention of non-cervical HPV disease. Secondary out-
comes concurrently collected during the L1-VLP trials included persis-
tent HPV infection for 6 and 12 months and immunogenicity up to 48
months after vaccination. Similar eﬃcacy rates for the prevention of
CIN2+ and the prevention of persistent HPV infection were found from
these trials [4]. These ﬁndings suggested the possibility of additional
appropriate clinical endpoints for next-generation vaccines. In order to
facilitate vaccine development, reduce eﬃcacy trial costs, and simplify
regulatory approval, the WHO aimed to evaluate alternate clinical trial
endpoints in parallel with the development of new vaccine candidates.
3. Identifying stakeholders and key questions
In February 2013, WHO held an initial scoping meeting in Geneva,
Switzerland, to identify the key stakeholders, process steps, and data
necessary to evaluate the evidence for potential alternate endpoints for
HPV vaccine trials. Participants at the scoping meeting included a
small gathering of experts across the WHO Secretariat, academia,
governmental scientiﬁc organizations, and regulatory agencies, along
with representation from the Bill and Melinda Gates Foundation
(BMGF). In order to determine whether there was adequate evidence
available to evaluate alternate clinical endpoints for HPV vaccine trials,
the following topics were brieﬂy reviewed: (1) the eﬃcacy of currently
approved prophylactic vaccinations; (2) an overview of HPV vaccine
candidates along the development pipeline [7]; (3) candidates for
alternate endpoints; (4) potential regulatory challenges; and (5) the
logistics of updating the WHO technical guidelines. The scope of this
particular meeting did not include other important aspects of HPV
vaccination, such as eﬃcacy as a therapeutic vaccination or a compre-
hensive review of vaccine safety.
As ﬁrst-generation vaccines have proven highly eﬃcacious against
HPV-16 and 18-associated cervical dysplasia [4], there was consensus
that placebo-controlled trials for next-generation vaccines would be
unethical. Consequently, powering a trial comparing current L1-VLP
vaccines to next-generation candidates with cervical dysplasia as the
primary outcome would likely prove prohibitive to vaccine develop-
ment, particularly if the trial were to take place among populations
having achieved herd immunity with current vaccines. Notably, during
the time period of these discussions, the phase III clinical trial for the
nonavalent vaccine (Gardasil-9, Merck) which covers HPV 6, 11, 16,
18, 31, 33, 45, 52, and 58, was conducted using the quadrivalent
vaccine as the control group [8]. Although it demonstrated greater
eﬃcacy, this trial required over 14,000 women and 6 years to complete.
Given the challenges with the current trial outcomes and the
signiﬁcant potential next-generation vaccines represent, the stage was
set to investigate alternative clinical endpoints that would prove
eﬃcacy and serve as surrogate outcomes for pre-cancer, but also would
allow for vaccine innovation, feasible clinical trials, and regulatory
approval. The discussions ultimately identiﬁed persistent HPV infec-
tion and vaccine titers as possible clinical endpoints.
The group identiﬁed individuals from the WHO, NIH, Centers for
Disease Control (CDC), and academic institutions representing inter-
national expertise in HPV epidemiology, natural history, laboratory
methods, and vaccine trials. Regulatory agencies from the United
States, China, European Union, and Canada, and pharmaceutical
companies currently developing vaccines, were also invited to be
crucial members of the discussion.
4. Scientiﬁc review on HPV epidemiology
The scoping group tasked the International Agency for Research on
Cancer (IARC), the specialized cancer agency of the WHO, and the
National Cancer Institute (NCI), a branch of the U.S. National
Institutes of Health (NIH), to jointly hold a scientiﬁc forum among
HPV experts to review the current knowledge on HPV epidemiology
and HPV-attributable disease, and consider persistent HPV infection
and immunogenicity as possible clinical endpoints. This meeting was
held in September 2013. The scientiﬁc opinion was established that use
of persistent HPV infection or immunogenicity, or rarely a disease
endpoint, for next-generation HPV vaccine trials was dependent on the
type of trial being designed [9]. The purpose of this manuscript is not
to summarize that report, but rather focus on how the scientiﬁc
consensus was translated into policy.
Fig. 1. (continued)
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5. How was consensus achieved?
Subsequent to the IARC/NCI meeting, a second meeting was
convened at the WHO in November 2013 with key experts and
stakeholders. A summary of the scientiﬁc review conducted by IARC/
NCI was ﬁrst presented [9]. Recommendations for clinical trial end-
points from the IARC working group based on age group ( < 16, 16–26,
> 26), anatomic site (cervix, anus, vulva, vagina, oropharynx), and
vaccine type (VLP, non-VLP) were discussed at length at the consensus
meeting [9]. As part of the discussion regarding appropriateness of
virologic endpoints, the importance of assay standardization used in
the clinical evaluation of HPV vaccines, e.g. virological (including
tissue/sample collection) and serological assays, was discussed. The
WHO Human Papillomavirus Laboratory Manual, which was devel-
oped by the former WHO HPV LabNet provided useful guidance and
information regarding assay standardization [10].
Given the strength of the scientiﬁc evidence, the group reached
consensus that persistent HPV infection greater than 6 months is an
appropriate clinical endpoint for HPV vaccine trials for L1 VLP
vaccines. The 6-month timeframe was agreed upon as clinical trial
data has shown the absolute risk of CIN3 is the same for persistent
infection for 6 or 12 months. A virologic endpoint would confer several
beneﬁts:
(1) smaller sample size for clinical trials;
(2) shorter trial length as incident HPV is more common than incident
dysplasia;
(3) applicability to various anatomic sites (i.e., cervix, anus, vulvar).
The group agreed on persistent HPV infection as a better endpoint
than a serologic endpoint for several reasons. Most notably, given rare
breakthrough infections with the current vaccines, the threshold of titer
level that confers immunity (immune correlate of protection) is
currently unknown [11]. This was felt to be one of the most signiﬁcant
drawbacks of a serologic endpoint, as the group agreed that future
vaccine trials should be designed as non-inferiority trials, which would
not be possible without an immune correlate of protection. In addition,
with various vaccine types (L2 VLP, non-VLP) in development and
plans for diﬀerent routes of administration, it is likely that the
protective antibody type and response would be diﬀerent by vaccine
type, thus requiring individual immune correlates of protection to be
established. However, in the longer term, as immunogenicity data
continues to mature especially with post-licensure data monitoring,
establishment of an immune correlate of protection may become
possible. Moreover, serologic non-inferiority for comparable vaccines
and immunobridging studies to younger age groups will continue to
serve as a core part of HPV vaccine trial research.
To further frame the discussion of applicable vaccine trial end-
points, regulators from the U.S. Food and Drug Administration (FDA)
and the European Medicines Agency (EMA) shared their perspective.
They agreed the scientiﬁc evidence was unequivocal that HPV is
necessary but not suﬃcient for cervical cancer and pointed to the
virologic endpoint data from prior vaccine trials as ample evidence for
adopting a new primary outcome for vaccine trials. They also high-
lighted the a priori need for ethical trials, prior to considering a vaccine
for licensure, thus ensuring that placebo-controlled trials would not be
an option.
Pharmaceutical companies innovating next-generation prophylactic
HPV vaccines shared information about the various candidates along
the development pipeline. They shared their support for virologic
primary endpoints, in part driven by the discussion of the long and
challenging nature of nonavalent vaccine trial design, powered on
disease endpoints.
At the conclusion of the meeting, persistent HPV infection greater
than 6 months was an acceptable and favored primary endpoint among
all interested parties.
6. Updating current WHO guidelines
When a need to establish or revise the standards is identiﬁed, WHO
organizes a consensus conference of relevant stakeholders (as deli-
neated in this document). In light of these formative discussions, a
drafting group preliminarily updates the guidelines, which are opened
for review for several months at a time and allow for public commen-
tary. The draft is then iteratively revised and reopened for feedback.
The drafting group is comprised of a multidisciplinary and interna-
tional group of experts and stakeholders, similar to the consensus
meeting but on a larger scale. Upon ﬁnalizing the guidelines, they are
presented to the WHO Expert Committee on Biological Standardization
(ECBS) for consideration. The ECBS helps guide the process that allows
countries to adopt the recommendations for the production and control
of vaccines. With approval, the updated guidelines become TRS.
After the above consensus was reached, the draft guidelines under-
went 4 rounds of commentary and revision prior to being presented to
the ECBS in 2015. At the annual meeting in October 2015, 2.5 years
after the initial scoping meeting took place, the revisions were adopted
[6].
7. Conclusion
The WHO plays a critical role in ensuring vaccine eﬃcacy and
safety, stimulating vaccine development, and allowing vaccine uptake
internationally. Although this is an important function of the WHO, the
process by which they achieve these goals has not previously been
delineated. With this manuscript, using the process to update guide-
lines on prophylactic HPV vaccines, we hope to have enhanced
transparency regarding this careful and deliberate process.
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